Glass House Brands (GLAS) Total Liabilities (2020 - 2026)
Glass House Brands' (GLAS) quarterly Total Liabilities came in at $147.9 million in Q1 2026, up 7.94% year-on-year from $137.0 million in Q1 2025, and up 2.74% on a QoQ basis from $144.0 million in Q4 2025.
Glass House Brands (GLAS) Total Liabilities (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has 7 years of Total Liabilities data on file, last reported at $147.9 million in Q1 2026.
- On a quarterly basis, Total Liabilities rose 7.94% year-over-year to $147.9 million in Q1 2026; TTM through Mar 2026 was $147.9 million, a 7.94% increase from a year earlier, with the FY2025 full-year figure at $144.0 million, down 1.7% from the prior year.
- Total Liabilities for Q1 2026 stood at $147.9 million, up from $144.0 million in the prior quarter.
- Over the last five years, Total Liabilities for GLAS reached as high as $170.6 million in Q3 2023 and fell as low as $110.2 million in Q1 2022.
- Historically, Total Liabilities has averaged $146.4 million across 5 years, with a median of $144.0 million in 2025.
- On a YoY basis, Total Liabilities climbed as much as 303.18% in 2022 and fell as far as 77.09% in 2022.
- Year by year, Total Liabilities stood at $129.5 million in 2022, then advanced by 22.43% to $158.5 million in 2023, then retreated by 7.63% to $146.4 million in 2024, then declined by 1.7% to $144.0 million in 2025, then rose by 2.74% to $147.9 million in 2026.
- Per Business Quant data, the three most recent Total Liabilities figures were $147.9 million in Q1 2026, $144.0 million in Q4 2025, and $138.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | 21.48 Bn |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 31.81 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 11.92 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 51.53 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 813.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | 21.08 Mn |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 22.18 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 1.50 Bn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 6.72 Bn |
| 10 | Glass House Brands | 873.84 Mn | 845.91 Mn | 10.02 Mn | 147.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 147.91 Mn |
| Dec 31, 2025 | 143.96 Mn |
| Sep 30, 2025 | 138.06 Mn |
| Jun 30, 2025 | 142.25 Mn |
| Mar 31, 2025 | 137.03 Mn |
| Dec 31, 2024 | 146.45 Mn |
| Sep 30, 2024 | 163.00 Mn |
| Jun 30, 2024 | 159.16 Mn |
| Mar 31, 2024 | 166.84 Mn |
| Dec 31, 2023 | 158.54 Mn |
| Sep 30, 2023 | 170.56 Mn |
| Jun 30, 2023 | 165.13 Mn |
| Mar 31, 2023 | 137.83 Mn |
| Dec 31, 2022 | 129.49 Mn |
| Sep 30, 2022 | 129.86 Mn |
| Jun 30, 2022 | 142.46 Mn |
| Mar 31, 2022 | 110.19 Mn |
| Dec 31, 2021 | 105.65 Mn |
| Sep 30, 2021 | 65.71 Mn |
| Jun 30, 2021 | 35.33 Mn |